Hugel Reports Record Net Sales and Profits in First Quarter of 2025

Hugel Inc. Achieves Record Earnings for Q1 2025

On May 8, 2025, Hugel Inc., a prominent figure in the global medical aesthetics sector, announced landmark financial results for the first quarter. The company recorded net sales of KRW89.8 billion, operating profit of KRW39.0 billion, and net profit of KRW30.9 billion. These results signify year-on-year increases of 20.9%, 62.6%, and 35.9%, respectively, marking Hugel's highest-ever earnings for a first quarter.

Hugel's growth has been robust across all its product lines, which include botulinum toxin, dermal fillers, and cosmetics. The flagship botulinum toxin product, Botulax, known globally as Letybo, contributed significantly to these figures, achieving net sales of KRW40.7 billion, representing an 18.8% increase compared to the previous year. This revenue alone accounted for a substantial 45% of the company’s total net sales in the first quarter, showcasing the strong demand for this product, particularly in the Asia-Pacific region, where it experienced a notable 54% surge in sales.

The company's hyaluronic acid fillers, including THE CHAEUM and BYRYZN Skin Booster HA, together brought in KRW34.4 billion during the same period, marking a 17.7% rise from the previous year. These products performed exceptionally well not only in Asia-Pacific markets but also gained traction in the Americas and Europe, including South Korea.

Hugel's cosmetics segment also recorded impressive figures, with total sales reaching KRW13.2 billion, which is a remarkable increase of 39.3%. The brands WELLAGE and BYRYZN BR continue to expand their portfolios and consumer reach by introducing new products and diversifying distribution channels both domestically and internationally.

A spokesperson from Hugel remarked, "This quarter's earnings are yet another testament to the robust growth across our entire product range globally. We aim to enhance our global footprint through strategic initiatives, including increased shipments to the US and market entry into the Middle East slated for the second quarter."

In line with its shareholder return policy, Hugel's board of directors has decided to retire 300,000 shares of treasury stock, effective May 15. This measure reflects the company's commitment to strengthening market trust and enhancing corporate value.

Founded in 2001, Hugel has established itself as a leader in medical aesthetics, especially in the production of injectable products for skin rejuvenation, including botulinum toxin, hyaluronic acid fillers, and skin boosters. As the top player in South Korea’s injectable aesthetics market, Hugel stands out as the sole South Korean firm with regulatory approvals to operate in the three largest global botulinum toxin markets: the United States, China, and Europe.

With a solid track record for safety and efficacy, Hugel is dedicated to advancing its industry through extensive medical affairs, comprehensive training, and dynamic forums. Over the last two decades, the company has expanded its reach to around 70 countries, boasting eight global subsidiaries in key markets like the US, Australia, Canada, and China. With a focus on leveraging strong industry momentum, Hugel is poised for continued growth and global market penetration.

In conclusion, Hugel's exemplary performance in Q1 2025 not only highlights its dominance in medical aesthetics but also sets a solid foundation for future initiatives aimed at fostering growth in both existing and new markets.